Table 1 The clinical and histopathological features of 23 cases
From: SP70 is a potential biomarker to identify gastric fundic gland neoplasms
Case sex | Age (years) | Group # | Ki67 | SP70 | Macroscopic type | Location | Size (mm) | Treatment | Pigment (/HPF) | Mitosis | Cellular atypia | Invasion depth | Vascular invasion | Ulcer | Follow up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. M | 38 | A | 1% | + | Protruding | Fundus | 6 | Biopsy+polypectomy | Absent | 0 | Mild | Mu | Absent | Absent | NED |
2. F | 57 | A | 2% | + | Protruding | Corpus | 6 | Polypectomy | Absent | 0 | Mild | Mu | Absent | Absent | NED |
3. F | 54 | A | 5% | − | Protruding | Corpus | 6 | Polypectomy | Absent | 0 | Mild | Mu | Absent | Absent | NED |
4. F | 59 | unclassified | 5% | − | Superficial elevated | Corpus | 7 | Surgery | Absent | 1 | Moderate | Mu | Absent | Absent | NED |
5. F | 80 | A | 2% | − | Protruding | Fundus | 6 | Polypectomy | Absent | 0 | Mild | Mu | Absent | Absent | NED |
6. M | 64 | A | 5% | − | Protruding | Corpus | 5 | Biopsy+ESD | Absent | 0 | Mild | Mu | Absent | Absent | NED |
7. F | 67 | A | 5% | − | Protruding | Corpus | 5 | EMR | Absent | 0 | Mild | Mu | Absent | Absent | NED |
8. M | 71 | A | 2% | − | Superficial elevated | Corpus | 15 | ESD | Absent | 0 | Mild | Mu | Absent | Absent | NED |
9. M | 68 | A | 5% | − | Superficial flat | Corpus | 5 | ESD | Absent | 0 | Mild | Mu | Absent | Absent | NED |
10. M | 51 | unclassified | 5% | − | Superficial elevated | Fundus | 15 | Proximal gastrectomy | Absent | 1 | Moderate | Mu | Absent | Absent | NED |
11. F | 66 | A | 2% | − | Protruding | Corpus | 6 | Biopsy | Absent | 0 | Mild | Mu | Absent | Absent | NED |
12. M | 73 | A | 5% | + | Protruding | Corpus | 10 | ESD | Absent | 0 | Mild | Mu | Absent | Absent | NED |
13. M | 60 | B | 10% | + | Protruding | Corpus | 10 | ESD | Absent | 0 | Mild | SM1(110μm) | Absent | Absent | NED |
14. M | 37 | C | 1% | − | Superficial flat | Corpus | 8 | ESD | Absent | 1 | Mild to moderate | SM1(363μm) | Present | Absent | NED |
15. M | 71 | C | 8% | + | Protruding | Fundus | 20 | EMR | Absent | 2 | Moderate | SM1(134μm) | Absent | Absent | NED |
16. F | 54 | B | 5% | + | Submucosal tumor | Fundus | 5 | Proximal gastrectomy | Absent | 0 | Mild | SM1(235μm) | Absent | Absent | NED |
17. M | 56 | C | 60% | − | Submucosal tumor | Fundus | 15 | ESD+total gastrectomy | Present | 1 | Marked | SM2(597μm) | Absent | Absent | NED |
18. M | 63 | B | 10% | − | Protruding | Fundus | 5 | ESD | Absent | 0 | Mild | SM1(100μm) | Absent | Absent | NED |
19. M | 45 | B | 10% | − | Superficial elevated | Fundus | 6 | ESD | Absent | 0 | Mild | SM1(159μm) | Absent | Absent | NED |
20. M | 55 | B | 2% | − | Superficial elevated | Corpus | 15 | ESD | Present | 0 | Mild | SM1(150μm) | Absent | Absent | NED |
21. F | 74 | B | 2% | − | Superficial elevated | Corpus | 6 | ESD | Absent | 0 | Mild | SM1(100μm) | Absent | Absent | NED |
22. F | 60 | B | 2% | − | Superficial elevated | Fundus | 8 | ESD | Absent | 0 | Mild to moderate | SM2(1500μm) | Absent | Absent | NED |
23. M | 71 | C | 15% | − | Infiltrative ulcerative | Corpus | 20 | Biopsy+total gastrectomy | Absent | 4 | Marked | Subserosa | Present | Present | 12* |